Volatiles in Breath and Headspace Analysis - Diagnostic Markers
Launched by UNIVERSITY OF LATVIA · Jul 21, 2017
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Study propose to explore a novel approach for the diagnosis and monitoring of diseases. The approach is based on the detection of volatile organic compounds (VOCs) that are emitted from the cells and detected directly from tissue, such as skin, surgery material, blood as well as from exhaled breath.
In the literature there are several reports on VOCs which can be detected by Gas Chromatography - Mass Spectrometry (GC-MS) means directly from: (i) the headspace of TB cells (i.e., the mixture of volatile biomarkers trapped above the TB cells in a sealed vessel); (ii) the exhaled breath or (ii...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed Consent signed
- • Individual with targeted disease/lesion (tuberculosis, gastric cancer, gastric dysplasia, high/ normal/ low risk gastric lesions, colorectal cancer, high-risk colorectal lesions, low-risk colorectal adenoma, pancreatic cancer, chronic pancreatitis, liver cancer, chronic liver disease, other infectious diseases, oncological diseases of other location)
- Exclusion Criteria:
- • Informed Consent not signed
- • Other active cancer at the time of inclusion for particular study group
About University Of Latvia
The University of Latvia is a leading academic institution dedicated to advancing knowledge and research in various fields, including medicine and health sciences. As a clinical trial sponsor, the University leverages its extensive expertise and resources to facilitate innovative research initiatives aimed at improving patient outcomes and contributing to the scientific community. The institution prioritizes ethical standards and regulatory compliance, ensuring that all trials are conducted with the utmost integrity and a commitment to participant safety. Through collaboration with healthcare professionals and researchers, the University of Latvia fosters an environment that encourages groundbreaking discoveries and enhances the quality of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Riga, , Latvia
Patients applied
Trial Officials
Mārcis Leja, PhD, MD
Study Director
University of Latvia
Lelde Lauka, MD
Principal Investigator
University of Latvia
Andra Cīrule, MD
Principal Investigator
Riga East University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials